-
EP4112641
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4112641
| EP4112641 - METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-GPC3 ANTIBODIES [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 10.10.2025 Database last updated on 08.04.2026 | |
| Former | Examination is in progress Status updated on 06.06.2025 | ||
| Former | Request for examination was made Status updated on 07.07.2023 | ||
| Former | The application has been published Status updated on 02.12.2022 | Most recent event Tooltip | 10.10.2025 | Withdrawal of application | published on 12.11.2025 [2025/46] | Applicant(s) | For all designated states CHUGAI SEIYAKU KABUSHIKI KAISHA 5-1, 5-chome Ukima Kita-ku Tokyo 115-8543 / JP | For all designated states GENENTECH, INC. 1 DNA Way South San Francisco, CA 94080 / US | [2023/01] | Inventor(s) | 01 /
ENDO, Mika Kamakura-shi Kanagawa 247-8530 / JP | 02 /
KATO, Atsuhiko Gotemba-shi Shizuoka 412-8513 / JP | 03 /
OHTOMO, Toshihiko Tokyo 103-8324 / JP | 04 /
ADACHI, Kenji Gotemba-shi Shizuoka 412-8513 / JP | 05 /
KINOSHITA, Yasuko Kamakura-shi Kanagawa 247-8530 / JP | [2023/01] | Representative(s) | Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstraße 3 81675 München / DE | [2023/01] | Application number, filing date | 21217994.9 | 14.03.2017 | [2023/01] | Priority number, date | JP20160051424 | 15.03.2016 Original published format: JP 2016051424 | [2023/01] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP4112641 | Date: | 04.01.2023 | Language: | EN | [2023/01] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 07.12.2022 | Classification | IPC: | C07K16/28, C07K16/30, A61K39/395, A61P35/00 | [2023/01] | CPC: |
C07K16/2827 (EP,CN,KR,US);
C07K16/303 (EP,CN,KR,US);
A61P35/00 (EP,CN,KR,US);
A61P43/00 (EP);
A61K2039/505 (EP,CN,KR);
A61K2039/507 (EP,CN,KR);
C07K2317/24 (CN,KR,US);
C07K2317/54 (US);
C07K2317/55 (US);
C07K2317/56 (US);
C07K2317/622 (US);
C07K2317/732 (CN,KR);
C07K2317/76 (EP,CN,KR,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/32] |
| Former [2023/01] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | VERFAHREN ZUR KREBSBEHANDLUNG MIT PD-1-ACHSENBINDENDEN ANTAGONISTEN UND ANTI-GPC3-ANTIKÖRPERN | [2023/01] | English: | METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-GPC3 ANTIBODIES | [2023/01] | French: | PROCÉDÉS DE TRAITEMENT DE CANCERS AU MOYEN D'ANTAGONISTES SE LIANT À L'AXE PD-1 ET D'ANTICORPS ANTI-GPC3 | [2023/01] | Examination procedure | 03.07.2023 | Amendment by applicant (claims and/or description) | 03.07.2023 | Examination requested [2023/32] | 03.07.2023 | Date on which the examining division has become responsible | 11.06.2025 | Despatch of a communication from the examining division (Time limit: M04) | 06.10.2025 | Application withdrawn by applicant [2025/46] | Parent application(s) Tooltip | EP17715545.4 / EP3430054 | Fees paid | Renewal fee | 28.01.2022 | Renewal fee patent year 03 | 28.01.2022 | Renewal fee patent year 04 | 28.01.2022 | Renewal fee patent year 05 | 28.01.2022 | Renewal fee patent year 06 | 14.02.2023 | Renewal fee patent year 07 | 15.02.2024 | Renewal fee patent year 08 | 14.02.2025 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I] WO2015112805 (REGENERON PHARMA et al.) | [I] EP2275135 (CHUGAI PHARMACEUTICAL CO LTD et al.) | [I] WO2015142675 (NOVARTIS AG et al.) | [PX] WO2017020812 (CARSGEN THERAPEUTICS LTD et al.) | [I] GHASSAN ABOU-ALF A ET AL: "Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170). | 2014 ASCO Annual Meeting | Abstracts | Meeting Library", JOURNAL OR CLINICAL ONCOLOGY, vol. 32, 30 May 2014 (2014-05-30), pages 5s, XP055371653 | [I] YU SAWADA ET AL: "Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 46, no. 1, 30 October 2014 (2014-10-30), GR, pages 28 - 36, XP055370119, ISSN: 1019-6439, DOI: 10.3892/ijo.2014.2737 DOI: http://dx.doi.org/10.3892/ijo.2014.2737 | [PX] ANONYMOUS ET AL: "A PHASE I STUDY OF CODRITUZUMAB, IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA", 22 July 2016 (2016-07-22), pages 1 - 2, XP055371632, Retrieved from the Internet | [A] A. X. ZHU ET AL: "First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma", CLINICAL CANCER RESEARCH, vol. 19, no. 4, 29 January 2013 (2013-01-29), pages 920 - 928, XP055207838, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-12-2616 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-12-2616 | by applicant | WO2010077634 | US8217149 | EP0404097 | WO9301161 | US4816567 | WO9824893 | WO9634096 | WO9633735 | WO9110741 | US5545807 | US5545806 | US5569825 | US5625126 | US5633425 | US5661016 | US6982321 | US7087409 | US6075181 | US6150584 | WO2007005874 | WO2013079174 | WO2011066389 | US2013034559 | WO2006121168 | WO2009114335 | WO2009101611 | WO2010027827 | WO2011066342 | WO2007137170 | WO03100429 | WO2006006693 | WO2007047291 | WO2009041062 | WO2009140242 | WO2007024249 | WO2007021841 | WO2006031370 | WO0042072 | WO2004029207 | WO2004099249 | WO2006105338 | WO2007041635 | WO2008092117 | WO2005070963 | WO2006020114 | WO2006116260 | WO2006023403 | WO2014097648 | WO2006046751 | US7189826 | US2006258841 | US2006183887 | US2006059575 | US2005287149 | US2005100546 | US2005026229 | US7078492 | US7153507 | US2005176122 | US6919436 | US5750373 | US2005079574 | US2005119455 | US2005266000 | US2007117126 | US2007160598 | US2007237764 | US2007292936 | US2009002360 | US5821337 | US7527791 | US5770429 | US7041870 | US2007061900 | US5869046 | WO9316185 | US5571894 | US5587458 | US5641870 | US6248516 | WO2008077546 | US2003157108 | US2004093621 | WO0061739 | WO0129246 | US2003115614 | US2002164328 | US2004132140 | US2004110704 | US2004110282 | US2004109865 | WO03085119 | WO03084570 | WO2005035586 | WO2005035778 | WO2005053742 | WO0231140 | WO2004056312 | WO03085107 | WO03011878 | US6602684 | US2005123546 | WO9730087 | WO9858964 | WO9922764 | US5500362 | WO2006029879 | WO2005100402 | US6737056 | US7332581 | US6194551 | WO9951642 | US2005014934 | US7371826 | US5648260 | US5624821 | WO9429351 | WO9013646 | US4965199 | EP0073657 | US4419446 | US4601978 | WO9411026 | DD266710 | US5648237 | US5789199 | US5840523 | EP0402226 | EP0183070 | EP0244234 | US5959177 | US6040498 | US6420548 | US7125978 | US6417429 | US4767704 | US4657866 | US4927762 | US4560655 | US5122469 | WO9003430 | WO8700195 | USRE30985 | US2005260186 | US2006104968 | US6267958 | US6171586 | WO2006044908 | WO2015095418 | LAFFERTY ET AL., AUST. J. EXP. BIOL. MED. SCI, vol. 53, 1975, pages 27 - 42 | BRETSCHER ET AL., SCIENCE, vol. 169, 1970, pages 1042 - 1049 | BRETSCHER, P.A., PROC. NAT. ACAD. SCI. USA, vol. 96, 1999, pages 185 - 190 | BRUGGEMANN, M. ET AL., J. EXP. MED., vol. 166, 1987, pages 1351 - 1361 | LENSCHOW ET AL., ANN. REV. IMMUNOL., vol. 14, 1996, pages 233 | OKAZAKI T ET AL., INTERN. IMMUN., vol. 19, no. 7, 2007, pages 813 | THOMPSON RH ET AL., CANCER RES, vol. 66, no. 7, 2006, pages 3381 | BLOOD, vol. 114, no. 8, 2009, pages 1537 | SHARPE ET AL., NAT REV, 2002 | KEIR ME ET AL., ANNU. REV. IMMUNOL., vol. 26, 2008, pages 677 | ANGEW CHEM. INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186 | MURAKAMI ET AL.: "The Molecular Basis of Cancer", 1995, W.B. SAUNDERS, article "Cell cycle regulation, oncogenes, and anti-neoplastic drugs" | CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628 | XU ET AL., IMMUNITY, vol. 13, 2000, pages 37 - 45 | LONBERG ET AL., NATURE, vol. 368, 1994, pages 812 - 813 | HUDSON ET AL., NAT. MED., vol. 9, 2003, pages 129 - 134 | JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 2551 - 6448 | KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495 - 97 | HONGO ET AL., HYBRIDOMA, vol. 14, no. 3, 1995, pages 253 - 260 | RIECHMANN ET AL., NATURE, vol. 322, 1988, pages 738 - 329 | HAMMERLING ET AL.: "Monoclonal Antibodies and T-Cell Hybridomas", 1981, ELSEVIER, pages: 563 - 681 | MARKS ET AL., J. MOL. BIOL., vol. 222, 1992, pages 581 - 597 | OKAZAKI ET AL., J. MOL. BIOL., vol. 336, no. 5, 2004, pages 1239 - 1249 | FELLOUSE, PROC. NATL. ACAD. SCI. USA, vol. 101, no. 34, 2004, pages 12467 - 12472 | LEE ET AL., J. IMMUNOL. METHODS, vol. 284, no. 1-2, 2004, pages 119 - 132 | HAMERS-CASTERMAN ET AL., NATURE, vol. 363, 1993, pages 446 - 448 | BRUGGEMANN ET AL., YEAR IN IMMUNOL, vol. 7, 1993, pages 33 | CARTER ET AL., BIO/ TECHNOLOGY, vol. 10, 1992, pages 163 - 167 | FISHWILD ET AL., NATURE BIOTECHNOL, vol. 14, 1996, pages 826 - 851 | LONBERGHUSZAR, INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93 | MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855 | JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525 | PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596 | VASWANIHAMILTON, ANN. ALLERGY, ASTHMA & IMMUNOL., vol. 1, 1998, pages 105 - 115 | HARRIS, BIOCHEM. SOC. TRANSACTIONS, vol. 23, 1995, pages 1035 - 1038 | HURLEGROSS, CURR. OP. BIOTECH., vol. 5, 1994, pages 428 - 433 | HOOGENBOOMWINTER, J. MOL. BIOL., vol. 222, 1991, pages 581 | BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81 | BOERNER ET AL., J. IMMUNOL., vol. 147, no. 1, 1991, pages 86 - 95 | VAN DIJKVAN DE WINKEL, CURR. OPIN. PHARMACOL., vol. 5, 2001, pages 368 - 74 | LI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 3557 - 3562 | CRAGG, M.S. ET AL., BLOOD, vol. 101, 2003, pages 1045 - 1052 | SHERIFF ET AL., NATURE STRUCT. BIOL., vol. 3, 1996, pages 733 - 736 | PADLAN, MOL. IMMUNOL., vol. 28, 1991, pages 489 - 498 | CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 | ZAPATA, PROTEIN ENG, vol. 8, no. 10, 1995, pages 1057 - 1062 | "UniProtKB", Database accession no. P51654.1 | "Current protocols in Immunology", 1993, article "Immunologic studies in humans" | ALLEY, CURR. OPIN. CHEM. BIOL., vol. 14, 2010, pages 529 - 537 | CHEN ET AL., J. MOL. BIOL., vol. 293, 1999, pages 865 - 881 | NI, XIANDAI MIANYIXUE, vol. 26, no. 4, 2006, pages 265 - 268 | VOLLMERSBRANDLEIN, HISTOLOGY AND HISTOPATHOLOGY, vol. 20, no. 3, 2005, pages 927 - 937 | VOLLMERSBRANDLEIN, METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol. 27, no. 3, 2005, pages 185 - 91 | RIPKA ET AL., ARCH. BIOCHEM. BIOPHYS., vol. 249, 1986, pages 533 - 545 | KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001 | BRODEUR ET AL.: "Monoclonal Antibody Production Techniques and Applications", 1987, MARCEL DEKKER, INC., pages: 51 - 63 | EVEN ET AL., TRENDS IN BIOTECHNOLOGY, vol. 24, no. 3, 2006, pages 105 - 108 | FRANEK, TRENDS IN MONOCLONAL ANTIBODY RESEARCH, 2005, pages 111 - 122 | BARNES ET AL., ANAL. BIOCHEM., vol. 102, 1980, pages 255 | STINCHCOMB ET AL., NATURE, vol. 282, 1979, pages 552 - 554 | WINTER ET AL., ANN. REV. IMMUNOL, vol. 12, 1994, pages 433 - 455 | GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734 | HOOGENBOOMWINTER, J. MOL. BIOL, vol. 227, 1992, pages 381 - 388 | ALMAGROFRANSSON, FRONT. BIOSCI., vol. 13, 2008, pages 1619 - 1633 | QUEEN ET AL., PROC. NAT'LACAD. SCI. USA, vol. 86, 1989, pages 10029 - 10033 | DALL'ACQUA ET AL., METHODS, vol. 36, 2005, pages 61 - 68 | KLIMKA ET AL., BR. J. CANCER, vol. 83, 2000, pages 252 - 260 | SIMS ET AL., J. IMMUNOL., vol. 151, 1993, pages 2296 | CARTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285 | PRESTA ET AL., J. IMMUNOL, vol. 151, 1993, pages 2623 | BACA ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 10678 - 10684 | ROSOK ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 22611 - 22618 | LONBERG, CURR. OPIN. IMMUNOL., vol. 20, 2008, pages 450 - 459 | LONBERG, NAT. BIOTECH., vol. 23, 2005, pages 1117 - 1125 | KOZBOR, J. IMMUNOL, vol. 133, 1984, pages 3001 | MORIMOTO ET AL., JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, vol. 24, 1992, pages 107 - 117 | CARTER ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 163 - 167 | CHOWDHURY, METHODS MOL. BIOL., vol. 207, 2008, pages 179 - 196 | CUNNINGHAMWELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085 | WRIGHT ET AL., TIBTECH, vol. 15, 1997, pages 26 - 32 | YAMANE-OHNUKI ET AL., BIOTECH. BIOENG., vol. 87, 2004, pages 614 | KANDA, Y. ET AL., BIOTECHNOL. BIOENG., vol. 94, no. 4, 2006, pages 680 - 688 | FERRARA ET AL., BIOTECHNOLOGY AND BIOENGINEERING, vol. 93, no. 5, 2006, pages 851 - 861 | RAVETCHKINET, ANNU. REV. IMMUNOL., vol. 9, 1991, pages 457 - 492 | HELLSTROM, I ET AL., PROC. NAT'LACAD. SCI. USA, vol. 83, 1986, pages 7059 - 7063 | HELLSTROM, I ET AL., PROC. NAT'LACAD. SCI. USA, vol. 82, 1985, pages 1499 - 1502 | CLYNES ET AL., PROC. NAT'LACAD. SCI. USA, vol. 95, 1998, pages 652 - 656 | GAZZANO-SANTORO ET AL., J. IMMUNOL. METHODS, vol. 202, 1996, pages 163 | CRAGG, M.S., M.J.GLENNIE, BLOOD, vol. 103, 2004, pages 2738 - 2743 | PETKOVA, S.B. ET AL., INT'L. IMMUNOL., vol. 18, no. 12, 2006, pages 1759 - 1769 | SHIELDS ET AL., J. BIOL. CHEM., vol. 9, no. 2, 2001, pages 6591 - 6604 | IDUSOGIE ET AL., J. IMMUNOL., vol. 164, 2000, pages 4178 - 4184 | GUYER ET AL., J. IMMUNOL., vol. 117, 1976, pages 587 | KIM ET AL., J. IMMUNOL., vol. 24, 1994, pages 249 | JONES, GENETICS, vol. 85, 1977, pages 12 | VAN DEN BERG, BIO/TECHNOLOGY, vol. 8, 1990, pages 135 | FLEER ET AL., BIO/TECHNOLOGY, vol. 9, 1991, pages 968 - 975 | REYES ET AL., NATURE, vol. 297, 1982, pages 598 - 601 | YAZAKIWU: "Methods in Molecular Biology", vol. 248, 2003, HUMANA PRESS, pages: 255 - 268 | GERNGROSS, NAT. BIOTECH., vol. 22, 2004, pages 1409 - 1414 | LI ET AL., NAT. BIOTECH., vol. 24, 2006, pages 210 - 215 | GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages 59 | MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251 | MATHER ET AL., ANNALS NY. ACAD. SCI., vol. 383, 1982, pages 44 - 68 | URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 | HAM ET AL., METH. ENZ., vol. 58, 1979, pages 44 | LINDMARK ET AL., J. IMMUNOL. METH., vol. 62, 1983, pages 1 - 13 | GUSS ET AL., EMBO J., vol. 5, 1986, pages 15671575 | "Antibodies, A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY | CHAMPE ET AL., J. BIOL. CHEM., vol. 270, 1995, pages 1388 - 1394 | "Remington's Pharmaceutical Sciences", 1980 | ISHIGURO T. ET AL., CANCER RES., vol. 68, 2008, pages 9832 - 9838 | SUZUKI ET AL., J TOXICOL SCI., vol. 27, 2002, pages 165 - 172 | WATANABE ET AL., J TOXICOL PATHOL., vol. 28, 2015, pages 43 - 49 |